Want to see VIR full AI Analyst Report?
Vir Biotechnology (VIR) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bulevirtide, Tobevibart, Elebsiran | Viral Hepatitis | Phase II | Recruiting | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Aug 19, 2025 | ― |
| Bulevirtide, Tobevibart, Elebsiran | Viral Hepatitis | Phase III | Recruiting | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | Aug 13, 2025 | ― |
| Pembrolizumab, Vir-5525 | Solid Tumor Malignancies, Egfr Positive Solid Tumors, Egfr | Phase I | Recruiting | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Apr 21, 2025 | ― |
| Tobevibart, Elebsiran | Viral Hepatitis | Phase III | Recruiting | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Mar 24, 2025 | ― |
| Vir-2218, Vir-3434, Vron-0200-Adc6, Vron-0200-Adc7 | Chronic Hepatitis B | Phase I | Active Not Recruiting | Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy | Sep 20, 2023 | ― |
| Enzalutamide, Darolutamide, Vir-5500 | Hormone-Refractory Prostate Cancer | Phase I | Recruiting | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | Jul 24, 2023 | ― |
| Vir-2218 | Renal Impairment | Phase I | Completed | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 | Apr 24, 2023 | ― |
| Peg-Ifnα, Tdf, Vir-2218, Vir-3434 | Hepatitis B, Chronic | phase1AndPhase2 | Active Not Recruiting | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | Nov 03, 2022 | ― |
| Vir-2218, Vir-3434 | Hepatic Impairment, Cirrhosis | Phase I | Recruiting | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 | Jul 15, 2022 | ― |
| Vir-2218, Vir-3434, Nrti | Hepatitis D, Chronic | Phase II | Active Not Recruiting | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | Jul 01, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bulevirtide, Tobevibart, Elebsiran | Phase II | Viral Hepatitis | Recruiting | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection | Aug 19, 2025 | ― |
| Bulevirtide, Tobevibart, Elebsiran | Phase III | Viral Hepatitis | Recruiting | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | Aug 13, 2025 | ― |
| Pembrolizumab, Vir-5525 | Phase I | Solid Tumor Malignancies, Egfr Positive Solid Tumors, Egfr | Recruiting | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Apr 21, 2025 | ― |
| Tobevibart, Elebsiran | Phase III | Viral Hepatitis | Recruiting | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection | Mar 24, 2025 | ― |
| Vir-2218, Vir-3434, Vron-0200-Adc6, Vron-0200-Adc7 | Phase I | Chronic Hepatitis B | Active Not Recruiting | Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy | Sep 20, 2023 | ― |
| Enzalutamide, Darolutamide, Vir-5500 | Phase I | Hormone-Refractory Prostate Cancer | Recruiting | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer | Jul 24, 2023 | ― |
| Vir-2218 | Phase I | Renal Impairment | Completed | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 | Apr 24, 2023 | ― |
| Peg-Ifnα, Tdf, Vir-2218, Vir-3434 | phase1AndPhase2 | Hepatitis B, Chronic | Active Not Recruiting | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection | Nov 03, 2022 | ― |
| Vir-2218, Vir-3434 | Phase I | Hepatic Impairment, Cirrhosis | Recruiting | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 | Jul 15, 2022 | ― |
| Vir-2218, Vir-3434, Nrti | Phase II | Hepatitis D, Chronic | Active Not Recruiting | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. | Jul 01, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Vir Biotechnology, Inc. (VIR) have in its pipeline
Vir Biotechnology VIR is currently developing the following drugs: Bulevirtide, Tobevibart, Elebsiran, Pembrolizumab, Vir-5525, Tobevibart, Elebsiran, Vir-2218, Vir-3434, Vron-0200-Adc6, Vron-0200-Adc7, Enzalutamide, Darolutamide, Vir-5500, Vir-2218, Peg-Ifnα, Tdf, Vir-2218, Vir-3434, Vir-2218, Vir-3434, Vir-2218, Vir-3434, Nrti, Pembrolizumab, Vir-5818, Peg-Ifnα, Vir-2218, Vir-3434. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
